» Articles » PMID: 29685954

Clinical Characteristics and Prognosis of Multiple Myeloma with Bone-related Extramedullary Disease at Diagnosis

Overview
Journal Biosci Rep
Specialty Cell Biology
Date 2018 Apr 25
PMID 29685954
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Multiple myeloma (MM) is a hematological neoplasm which results in diffuse or focal bone infiltration and extramedullary lesions. It's reported that infiltration of organs by plasma cells indicated worse prognosis, but the prognosis of patients with bone-related extramedullary disease (bEMD) is still unknown. One hundred and fourteen newly diagnosed MM patients were retrospectively reviewed. Results showed that the clinical features, overall survival (OS), and progression-free survival (PFS) of patients with and without bEMD had no statistical significance. Rib (46.1%) and vertebrae (17.9%) are common sites bEMD involved. Patients with diffuse bEMD had worse prognosis compared with patients with focal bEMD. Bisphosphonates played an important role in prolonging the survival of patients with bEMD. Positron emission tomography (PET)/computed tomography (CT) is sensitive in discovering bEMD than whole body low dose CT suggesting PET/CT to be a promising technique for initial staging. High β2-microglobulin and low albumin indicated shorter survival in patients with bEMD.

Citing Articles

Interaction between age and gender on survival outcomes in extramedullary multiple myeloma over the past two decades.

Bangolo A, Fwelo P, Trivedi C, Sagireddy S, Aljanaahi H, Auda A World J Clin Oncol. 2023; 14(4):179-189.

PMID: 37124133 PMC: 10134202. DOI: 10.5306/wjco.v14.i4.179.


Negative E-cadherin expression on bone marrow myeloma cell membranes is associated with extramedullary disease.

Hirao M, Yamazaki K, Watanabe K, Mukai K, Hirose S, Osada M F1000Res. 2022; 11:245.

PMID: 35646332 PMC: 9117942. DOI: 10.12688/f1000research.109551.2.


Comparison of clinical characteristics, treatment efficacy and survival in patients with newly diagnosed multiple myeloma with single- versus multi-site extramedullary invasion.

Zhao Y, Zhou F J Cancer Res Clin Oncol. 2022; 149(3):995-1006.

PMID: 35212816 DOI: 10.1007/s00432-022-03948-9.


Effects of Amyloid Light-Chain Amyloidosis on Clinical Characteristics and Prognosis in Multiple Myeloma: A Single-Center Retrospective Study.

Xu J, Wang M, Shen Y, Yan M, Xie W, Wang B Cancer Manag Res. 2021; 13:1343-1356.

PMID: 33603480 PMC: 7884938. DOI: 10.2147/CMAR.S287922.

References
1.
Varettoni M, Corso A, Pica G, Mangiacavalli S, Pascutto C, Lazzarino M . Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients. Ann Oncol. 2009; 21(2):325-330. DOI: 10.1093/annonc/mdp329. View

2.
Lutje S, Rooy J, Croockewit S, Koedam E, Oyen W, Raymakers R . Role of radiography, MRI and FDG-PET/CT in diagnosing, staging and therapeutical evaluation of patients with multiple myeloma. Ann Hematol. 2009; 88(12):1161-8. PMC: 2763177. DOI: 10.1007/s00277-009-0829-0. View

3.
Morgan G, Davies F, Gregory W, Cocks K, Bell S, Szubert A . First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. Lancet. 2010; 376(9757):1989-99. PMC: 3639680. DOI: 10.1016/S0140-6736(10)62051-X. View

4.
Short K, Rajkumar S, Larson D, Buadi F, Hayman S, Dispenzieri A . Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma. Leukemia. 2011; 25(6):906-8. PMC: 3736849. DOI: 10.1038/leu.2011.29. View

5.
Blade J, Fernandez de Larrea C, Rosinol L, Cibeira M, Jimenez R, Powles R . Soft-tissue plasmacytomas in multiple myeloma: incidence, mechanisms of extramedullary spread, and treatment approach. J Clin Oncol. 2011; 29(28):3805-12. DOI: 10.1200/JCO.2011.34.9290. View